Hematology

Data from the Phase 1/2 BEACON trial indicate the efficacy and safety of this investigative 1-time therapy, particularly in decreasing blood cell sickling.

Hereditary hemorrhagic telangiectasia has no approved treatments; this designation, in addition to the European Medicines Agency granting a positive opinion, positions DIAG723 to be the first.

Investigators also noted the risk of Hb overshoot in patients switching from ESA to roxadustat, emphasizing the importance of monitoring Hb levels before and after treatment.

An audio recap of the top 5 stories in healthcare news from the week of 06/02-06/08.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and new phase 3 clinical trial data, in this week's essential news roundup.

An ongoing phase 1 study aims to prove the safety and tolerability of VAS-101, as well as its effect on blood flow dynamics, red blood cell sickling, and oxygen dissociation.

Novartis has announced the safety and efficacy of iptacopan, a twice-daily oral monotherapy for adult patients who switched from eculizumab or ravulizumab.

If approved, mavorixafor will be the second FDA-approved treatment and the first oral medication for CN.

Investigators compared the medications across various patient cohorts with different causes of anemia, finding evidence almost uniformly in favor of FCM.

A recent analysis reveals no significant difference between restrictive and liberal transfusion strategies on quality of life in patients with myocardial infarction and anemia.

A relatively quiet month for hematology, marked by brief ups and downs for trials and new research on anemia and sickle cell disease.

Investigators examined emergency department utilization as a product of age, patient-reported severity of vaso-occlusive episodes, and Social Vulnerability Index score.

Iron deficient diets can lead to anemia and various other health complications in adulthood.

Iron deficiency affects millions globally, especially women, yet remains underdiagnosed. Regular screening can prevent severe health issues and improve lives.

Prothena halts birtamimab development after missing key Phase 3 trial endpoints for AL amyloidosis, prompting workforce reductions and cost-cutting measures.

Stay updated with the latest healthcare breakthroughs, including FDA approvals and innovative treatments, in this week's essential news roundup for professionals.

Interim results from the ongoing trial indicated achievement of all efficacy endpoints, with no safety concerns reported.

A study reveals a significant link between iron deficiency anemia and increased ischemic stroke risk in young adults, highlighting urgent screening needs.

A mixture of thalidomide and hydroxyurea outperformed hydroxyurea alone in all primary outcomes.

Anemia can moderate the association between both conditions, increasing the risk of atherosclerotic cardiovascular disease.

Investigators believe the connection may account for a substantial number of anemia cases in children.

Anemia correction reduced perioperative rates but showed no significant impact on postoperative outcomes, emphasizing the need for prehabilitation strategies.

Despite no direct correlation being identified, this research highlights a potential association between the two conditions.

Investigators examined the safety of the recalled sickle cell disease medication through retrospective analysis of an FDA database.

Investigators encourage further study of treatment and therapy methods for childhood IBD.